Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase
The preferred route of administration for an injected therapeutic agent is subcutaneous (SC), but SC injections are generally limited to no more than 1-2 mL in volume, representing a major challenge, especially for large protein biologics.


Pharmaceutical Technology


33. A.B. Csoka, G.I. Frost, and R. Stern, "The Six Hyaluronidase-like Genes in the Human and Mouse Genomes," Matrix Biol. 20 (8), 499–508 (2001).

34. Y. Lin et al., "A Hyaluronidase Activity of the Sperm Plasma Membrane Protein PH-20 Enables Sperm to Penetrate the Cumulus Cell Layer Surrounding the Egg," J. Cell. Biol. 125 (5), 1157–1163 (1994).

35. G.N. Cherr et al., "The PH-20 Protein in Cynomolgus Macaque Spermatozoa: Identification of Two Different Forms Exhibiting Hyaluronidase Activity," Dev. Biol. 175 (1), 142–153 (1996).

36. P. Gacesa, N.D. Civill, and R.A. Harrison, "PH-20 and Sperm Hyaluronidase: A Conceptual Conundrum in Mammalian Fertilization," Biochem. J. 303 (Pt. 1), 335–336 (1994).

37. G.I. Frost and R. Stern, "A Microtiter-based Assay for Hyaluronidase Activity not Requiring Specialized Reagents," Anal. Biochem. 251 (2), 263–269 (1997).

38. L.H. Bookbinder et al., "A Recombinant Human Enzyme for Enhanced Interstitial Transport of Therapeutics," J. Control Release 114 (2), 230–241 (2006).

39. H.D. Keiser and V.B. Hatcher, "The Effect of Contaminant Proteases in Testicular Hyaluronidase Preparations on the Immunologic Properties of Bovine Nasal Cartilage Proteoglycan," Connect Tissue Res. 6 (4), 229–233 (1979).

40. V.M. Doctor, H. Spence, and E.Y. Carroll, "Isolation and Properties of a New Anticoagulant Protein from Commercial Bovine Testicular Hyaluronidase," Thromb. Res. 30 (6), 565–571 (1983).

41. M. Hyuga, R. Kodama, and G. Eguchi, "Basic Fibroblast Growth Factor as One of the Essential Factors Regulating Lens Transdifferentiation of Pigmented Epithelial Cells," Int. J. Dev. Biol. 37 (2), 319–326 (1993).

42. J.C. Houck and C.M. Chang, "Permeability Factor Contaminating Hyaluronidase Preparations," Inflammation 3 (4), 447–451 (1979).

43. M. Oettl et al., "Comparative Characterization of Bovine Testicular Hyaluronidase and a Hyaluronate Lyase from Streptococcus agalactiae in Pharmaceutical Preparations," Eur. J. Pharm. 18 (3–4), 267–277 (2003).

44. M.F. Haller et al., "Escaping the Interstitial Matrix with Enzyme-Mediated Drug Delivery," Drug Delivery Technol. 5 (5), 40–45 (2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here